Table 1.
Baseline characteristics of the study population
| Aspirin | Placebo | |
|---|---|---|
| Total population | ||
| n | 19,326 | 19,390 |
| Age category (%) | ||
| 45–54 years | 60.6 | 60.6 |
| 55–64 years | 29.2 | 29.2 |
| ≥65 years | 10.2 | 10.1 |
| BMI category (%) | ||
| <25.0 kg/m2 | 51.8 | 51.8 |
| 25.0–29.9 kg/m2 | 30.8 | 31.0 |
| ≥30.0 kg/m2 | 17.4 | 17.2 |
| Ethnicity (%) | ||
| White not of Hispanic origin | 95.1 | 95.0 |
| African American | 2.3 | 2.1 |
| Hispanic | 1.0 | 1.1 |
| American Indian or Alaskan Native | 0.3 | 0.2 |
| Asian or Pacific Islander | 1.3 | 1.5 |
| Unknown (none of the above) | 0.2 | 0.2 |
| Family history of diabetes (%)* | 24.6 | 25.1 |
| Current smoker (%) | 12.9 | 13.4 |
| Exercise ≥ once weekly (%)† | 42.4 | 41.8 |
| Alcohol consumption ≥ once weekly (%) | 42.4 | 42.5 |
| History of hypertension (%) | 24.9 | 24.7 |
| History of hyperlipidemia (%) | 29.5 | 28.5 |
| Postmenopausal (%) | 54.6 | 53.9 |
| Baseline use of hormone therapy (%) | 41.6 | 40.9 |
| Available baseline blood specimen | ||
| n | 13,595 | 13,572 |
| Total cholesterol (mmol/l) | 5.41 (4.76–6.10) | 5.38 (4.76–6.08) |
| LDL cholesterol (mmol/l) | 3.15 (2.60–3.74) | 3.13 (2.60–3.72) |
| HDL cholesterol (mmol/l) | 1.35 (1.13–1.62) | 1.35 (1.12–1.61) |
| Total cholesterol–to–HDL cholesterol ratio | 4.0 (3.2–4.9) | 3.9 (3.2–4.9) |
| Non-HDL cholesterol(mmol/l) | 3.99 (3.33–4.72) | 3.98 (3.34–4.68) |
| A1C (%) | 5.0 (4.8–5.2) | 5.0 (4.8–5.2) |
| hsCRP (mg/l) | 2.0 (0.8–4.2) | 2.0 (0.8–4.3) |
Data are % or median (interquartile range).
*
Family history of diabetes in a first-degree relative (mother, father, sister, or brother).
†
Physical activity defined by number of episodes of vigorous physical activity per week.